The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Borrower

G•••••• B••••••••• I••• a••

Drug Discovery & Developmentgroup grade Aoff every schedule since Dec 31, 2025sponsor unattributed
See every lender's markFind rescue capital
More
Special situations PE firms

Nothing material in the last 200 days. No dated change on record yet.

Principal held
at least $67.1M
sum of BDC pieces, a lower bound
Fair value
$66.7M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Apr 1, 2029
no dated debt inside 24 months
On the tape since
Dec 31, 2025
latest Dec 31, 2025
Events
2
dated, non-routine
Lender marks
each lender's own fair value over cost at Dec 31, 2025, folded to one row per lender
LenderExposureCurrent markQoQ change
H••••••• C••••••• I•••$67.1M100¢new this quarter
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
BDCInstrumentPrincipalFair valueRate
H••••••• C••••••• I•••term loan first lien
S••••• S•••••• and M••••••• D••• A•••• 2029 and P•••• + 2.45%, F•••• rate 9.45%, 6.45% E••
$67.1M$66.7M
100c
S+245 bp
Capital structure as the BDCs see it
latest quarter end Dec 31, 2025
FacilityHeldOn costPricingMaturityBDCs
first lien term loan first lien
exited Dec 31, 2025
at least $67.1M100cS+245 bpApr 1, 20291
Through time
the borrower's pieces summed across BDCs, every quarter end
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Dec 31, 20251$67.1M$66.7M100c0
What changed
Every change including routine ones
Identity
Group key
GENETIX BIOTHERAPEUTICS ANDderivedthe codename stem after legal suffixes and deal words
Spellings
1 across 1 BDCderived
Industry
Drug Discovery & Developmentreportedas one filer wrote it